<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

E 3810 dihydrochloride - AL 3810 dihydrochloride | Lucitanib

產(chǎn)品貨號(hào)

Axon 1942 CAS [N.A.] MF C26H25N3O4.2HClMW 516.42 Purity: 99% Soluble in water and DMSO Description First-in-class dual VEGFR/FGFR tyrosine kinase inhibitor; E-3810 potently and selectively inhibited VEGFR1, -2, and -3 and FGFR-1 and -2 kinases in the nanomolar range; a potent antiangiogenic small molecule with a favorable pharmacokinetic profile and broad spectrum antitumor activity References Certificates Categories Extra info E Bello et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011, 71(4), 1396-1405.? ? JC Soria et al. First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. Ann. Oncol. 2011, 22, 40.? ? Y Zhou et al. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J. Cell Mol. Med. 2012, 16(10), 2321-2330.? ? G Damia et al. Is PDGFR an important target for E-3810? J. Cell Mol. Med. 2012, 16(11), 2838-2839.?[Letter to the Editor] Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology VEGFR RTK class IV and V; EC 2.7.10.1 FGFR Dual VEGFR/FGFR tyrosine kinase inhibitor Chemical name 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide dihydrochloride Parent CAS No. [1058137-23-7] Order Size Unit Price Stock 2 mg €95.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

E 3810 dihydrochloride - AL 3810 dihydrochloride | Lucitanib

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 1942

CAS [N.A.]

MF C26H25N3O4.2HCl
MW 516.42

Purity: 99%
Soluble in water and DMSO

E 3810 dihydrochloride

Description

First-in-class dual VEGFR/FGFR tyrosine kinase inhibitor; E-3810 potently and selectively inhibited VEGFR1, -2, and -3 and FGFR-1 and -2 kinases in the nanomolar range; a potent antiangiogenic small molecule with a favorable pharmacokinetic profile and broad spectrum antitumor activity

E Bello et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011, 71(4), 1396-1405.?

JC Soria et al. First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. Ann. Oncol. 2011, 22, 40.?

Y Zhou et al. AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J. Cell Mol. Med. 2012, 16(10), 2321-2330.?

G Damia et al. Is PDGFR an important target for E-3810? J. Cell Mol. Med. 2012, 16(11), 2838-2839.?[Letter to the Editor]

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Cell Signaling & Oncology VEGFR RTK class IV and V; EC 2.7.10.1 FGFR

Dual VEGFR/FGFR tyrosine kinase inhibitor

Chemical name

6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide dihydrochloride

Parent CAS No.

[1058137-23-7]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>